High-content drug screening with engineered musculoskeletal tissues

Tissue Engineering - Part B: Reviews

Volumn 16, Issue 1, 2010, Pages 55-64

  Vandenburgh, Herman ^a,b  

^a MIRIAM HOSPITAL   (United States)

^b Myomics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVE AREA; ANIMAL STUDIES; AUTOMATED FUNCTIONAL TESTING; BIOCHEMICAL REACTIONS; CLINICAL APPLICATION; COST EFFECTIVE; DRUG-SCREENING; ENGINEERED TISSUES; FORCE GENERATION; HIGH-CONTENT; HIGH-CONTENT SCREENING; HIGH-THROUGHPUT; IN-VITRO; IN-VIVO; MULTIPLE PATHWAYS; MUSCULOSKELETAL DISORDERS; POSITIVE AND NEGATIVE EFFECT; SKELETAL MUSCLE; SMALL ANIMAL; TISSUE FUNCTION; TRANSLATIONAL RESEARCH;

ANIMALS; COST REDUCTION; GENE EXPRESSION; HISTOLOGY; MECHANICAL PROPERTIES; MUSCLE; TISSUE ENGINEERING;

BIOMECHANICS;

AUTOANALYSIS; BONE; CARTILAGE; COST EFFECTIVENESS ANALYSIS; DRUG SCREENING; HUMAN; INTERVERTEBRAL DISK; MUSCLE CONTRACTION; MUSCLE FATIGUE; MUSCLE RELAXATION; MUSCLE TISSUE; MUSCULOSKELETAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; TENDON; TISSUE ENGINEERING; TISSUE REPAIR;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MUSCULOSKELETAL SYSTEM; TISSUE ENGINEERING;

ANIMALIA;

EID: 76749122400     PISSN: 19373368     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.teb.2009.0445     Document Type: Review

References (93)

1. Vandenburgh, H.H., Swasdison, S., and Karlisch, P. Computer aided mechanogenesis of skeletal muscle organs from single cells in vitro. FASEB J 5, 2860, 1991.
2. Langer, R., and Vacanti, J.P. Tissue engineering. Science 260, 920, 1993.
3. Griffith, L.G., and Naughton, G. Tissue engineering-current challenges and expanding opportunities. Science 295, 1009, 2002.
4. Khademhosseini, A., Langer, R., Borenstein, J., and Vacanti, J.P. Tissue engineering special feature: microscale technologies for tissue engineering and biology. Proc Natl Acad Sci USA 103, 2480, 2006.
5. Terstappen, G.C., Schlupen, C., Raggiaschi, R., and Gavir-aghi, G. Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 6, 891, 2007.
6. Dove, A. Screening for content-the evolution of high throughput. Nat Biotech 21, 859, 2003.
7. Wermuth, C.G. Selective optimization of side activities: another way for drug discovery. J Med Chem 47, 1303, 2004.
8. Sams-Dodd, F. Target-based drug discovery: is something wrong? Drug Discov Today 10, 139, 2005.
9. O'Connor, K.A., and Roth, B.L. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 4, 1005, 2005.
10. Ashburn, T.T., and Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3, 673, 2004.
11. Chamberlain, J.S., and Rando, T.A. Duchenne muscular dystrophy: Advances in Therapeutics. Informa Healthcare, New York, NY, 2006.
12. Barton-Davis, E.R., Cordier, L., Shoturma, D.I., Leland, S.E., and Sweeney, H.L. Aminoglycoside antibiotics restore dys-trophin function to skeletal muscles of mdx mice. J Clin Invest 104, 375, 1999.
13. Cohn, R.D., van Erp, C., Habashi, J.P., Soleimani, A.A., Klein, E.C., Lisi, M.T., Gamradt, M., Ap Rhys, C.M., Holm, T.M., Loeys, B.L., Ramirez, F., Judge, D.P., Ward, C.W., and Dietz, H.C. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 13, 204, 2007.
14. Boguski, M.S., Mandl, K.D., and Sukhatme, V.P. Repurpos-ing with a difference. Science 324, 1394, 2009.
15. Sivaraman, A., Leach, J.K., Townsend, S., Iida, T., Hogan, B.J., Stolz, D.B., Fry, R., Samson, L.D., Tannenbaum, S.R., and Griffith, L.G. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 6, 569, 2005.
16. Khetani, S.R., and Bhatia, S.N. Microscale culture of human liver cells for drug development. Nat Biotechnol 26, 120, 2008.
17. Eschenhagen, T., and Zimmermann, W.H. Engineering myocardial tissue. Circ Res 97, 1220, 2005.
18. Fischbach, C., Chen, R., Matsumoto, T., Schmelzle, T., Brugge, J.S., Polverini, P.J., and Mooney, D.J. Engineering tumors with 3D scaffolds. Nat Meth 4, 855, 2007.
19. Yliperttula, M., Chung, B.G., Navaladi, A., Manbachi, A., and Urtti, A. High-throughput screening of cell responses to biomaterials. Eur J Pharm Sci 35, 151, 2008.
20. Jongpaiboonkit, L., King, W.J., and Murphy, W.L. Screening for 3D environments that support human mesenchymal stem cell viability using hydrogel arrays. Tissue Eng Part A 15, 343, 2009.
21. Peters, A., Brey, D.M., and Burdick, J.A. High-throughput and combinatorial technologies for tissue engineering applications. Tissue Eng Part B 15, 225, 2009.
22. Evaluation criteria for musculoskeletal and craniofacial tissue engineering constructs: a conference report. Tissue Eng Part A 14, 2089, 2008.
23. Mikos, A.G., Herring, S.W., Ochareon, P., Elisseeff, J., Lu, H.H., Kandel, R., Schoen, F.J., Toner, M., Mooney, D., Atala, A., Van Dyke, M.E., Kaplan, D., and Vunjak-Novakovic, G. Engineering complex tissues. Tissue Eng 12, 3307, 2006.
24. Hsu, S.H., Tsai, C.L., and Tang, C.M. Evaluation of cellular affinity and compatibility to biodegradable polyesters and Type-II collagen-modified scaffolds using immortalized rat chondrocytes. Artif Organs 26, 647, 2002.
25. Yang, J., Cao, C., Wang, W., Tong, X., Shi, D., Wu, F., Zheng, Q., Guo, C., Pan, Z., Gao, C., and Wang, J. Proliferation and osteogenesis of immortalized bone marrow-derived mesen-chymal stem cells in porous polylactic glycolic acid scaffolds under perfusion culture. J Biomed Mater Res A 2009. [Epub ahead of print].
26. Stringer, B., Waddington, R., Sloan, A., Phillips, I., Telford, G., Hughes, D., Craig, G., Gangemi, L., Brook, I., Freeman, C., Cao, X., Gosal, M., Smith, S., Russell, G., and Foster, G. Bespoke human hypertrophic chondrocytic cell lines provide the osteoinductive signals required for vascularized bone formation. Tissue Eng 13, 133, 2007.
27. Kubota, M., Chiba, M., Obinata, M., Ueda, S., and Mitani, H. Establishment of periodontal ligament cell lines from temperature-sensitive Simian virus 40 large T-antigen transgenic rats. Cytotechnology 44, 55, 2004.
28. Butler, D.L. Juncosa-Melvin, N., Boivin, G.P., Galloway, M.T., Shearn, J.T., Gooch, C., and Awad, H. Functional tissue engineering for tendon repair: a multidisciplinary strategy using mesenchymal stem cells, bioscaffolds, and mechanical stimulation. J Ortho Res 26, 1, 2008.
29. Napolitano, A.P., Dean, D.M., Man, A.J., Youssef, J., Ho, D.N., Rago, A.P., Lech, M.P., and Morgan, J.R. Scaffold-free three-dimensional cell culture utilizing micromolded non-adhesive hydrogels. BioTechniques 43, 494, 2007.
30. Stanton, L., Sabari, S., Sampaio, A.V., Underhill, T.M., and Beier, F. p38 MAP kinase signalling is required for hyper-trophic chondrocyte differentiation. Biochem J 378, 53, 2004.
31. Huang, A., Motlekar, N., Stein, A., Diamond, S., Shore, E., and Mauck, R. High-throughput screening for modulators of mesenchymal stem cell chondrogenesis. Ann Biomed Eng 36, 1909, 2008.
32. Vunjak-Novakovic, G., Altman, G., Horan, R., and Kaplan, D.L. Tissue engineering of ligaments. Annu Rev Biomed Eng 6, 131, 2004.
33. Frohlich, M., Grayson, W.L., Wan, L.Q., Marolt, D., Drobnic, M., and Vunjak-Novakovic, G. Tissue engineered bone grafts: biological requirements, tissue culture and clinical relevance. Curr Stem Cell Res Ther 3, 254, 2009.
34. Buma, P., Schreurs, W., and Verdonschot, N. Skeletal tissue engineering-from in vitro studies to large animal models. Biomaterials 25, 1487, 2004.
35. Petrigliano, F.A., McAllister, D.R., and Wu, B.M. Tissue engineering for anterior cruciate ligament reconstruction: a review of current strategies. Arthroscopy 22, 441, 2006.
36. Marquez, J.P., Legant, W., Lam, V., Cayemberg, A., Elson, E., and Wakatsuki, T. High-throughput measurements of hydrogel tissue construct mechanics. Tissue Eng Part C Methods 15, 181, 2009.
37. Hill, E., Boontheekul, T., and Mooney, D.J. Regulating activation of transplanted cells controls tissue regeneration. Proc Natl Acad Sci USA 103, 2494, 2006.
38. Shansky, J., Ferland, P., McGuire, S., Powell, C., Del Tatto, M., Nachman, M., Hennessey, J., and Vandenburgh, H. Tissue engineering human skeletal muscle for clinical applications. In: Vunjak, G., and Freshney, I., eds. Culture of Cells for Tissue Engineering. Hoboken NJ: Wiley, 2006, pp. 239-257.
39. Vandenburgh, H., Chromiak, J., Shansky, J., DelTatto, M., and LeMaire, J. Space travel directly induces skeletal muscle atrophy. FASEB J 13, 1031, 1999.
40. Mooney, D.J., and Vandenburgh, H. Cell delivery mechanisms for tissue repair. Cell Stem Cell 2, 205, 2008.
41. Bader, D.L., and Knight, M.M. Biomechanical analysis of structural deformation in living cells. Med Biol Eng Comput 46, 951, 2008.
42. Vandenburgh, H.H., and Kaufman, S. In vitro model for stretch-induced hypertrophy of skeletal muscle. Science 203, 265, 1979.
43. Burkholder, T.J. Mechanotransduction in skeletal muscle. Front Biosci 12, 174, 2007.
44. Peault, B., Rudnicki, M., Torrente, Y., Cossu, G., Tremblay, J.P., Partridge, T., Gussoni, E., Kunkel, L.M., and Huard, J. Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 15, 867, 2007.
45. Sacco, A., Doyonnas, R., Kraft, P., Vitorovic, S., and Blau, H.M. Self-renewal and expansion of single transplanted muscle stem cells. Nature 456, 502, 2008.
46. Cross-Doersen, D., and Isfort, R.J. A novel cell-based system for evaluating skeletal muscle cell hypertrophy-inducing agents. In Vitro Cell Dev Biol Anim 39, 407, 2003.
47. Zhu, C.H., Mouly, V., Cooper, R.N., Mamchaoui, K., Bigot, A., Shay, J.W., Di Santo, J.P., Butler-Browne, G.S., and Wright, W.E. Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell 6, 515, 2007.
48. Friesen, W., Acharjee, S., Zhuo, J., Baiazitov, R., Lee, S., Moon, Y.C., Sweeney, H.L., and Welch, E. Identification and characterization of small molecules for the treatment of Duchenne muscular dystrophy. Neuromuscul Disord 18, 812,2008.
49. Courdier-Fruh, I., Barman, L., Briguet, A., and Meier, T. Glucocorticoid-mediated regulation of utrophin levels in human muscle fibers. Neuromuscul Disord 12(Suppl 1), S95, 2002.
50. Vandenburgh, H.H., Karlisch, P., Shansky, J., and Feldstein, R. Insulin and insulin-like growth factor-1 induce pronounced hypertrophy of skeletal myofibers in tissue culture. Am J Physiol Cell Physiol 260, C475, 1991.
51. Semsarian, C., Wu, M.J., Ju, Y.K., Marciniec, T., Yeoh, T., Allen, D.G., Harvey, R.P., and Graham, R.M. Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway. Nature 400, 576, 1999.
52. Bodine, S.C., Latres, E., Baumhueter, S., Lai, V.K., Nunez, L., Clarke, B.A., Poueymirou, W.T., Panaro, F.J., Na, E., Dhar-marajan, K., Pan, Z.Q., Valenzuela, D.M., DeChiara, T.M., Stitt, T.N., Yancopoulos, G.D., and Glass, D.J. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704, 2001.
53. Jiang, Z., and Clemens, P.R. Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells. FASEB J 20, 2570, 2006.
54. Granchelli, J.A., Pollina, C., and Hudecki, M.S. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 10, 235, 2000.
55. Glass, D.J. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol 5, 87, 2003.
56. Payne, E.T., Yasuda, N., Bourgeois, J.M., Devries, M.C., Rodriguez, M.C., Yousuf, J., and Tarnopolsky, M.A. Nutritional therapy improves function and complements cortico-steroid intervention in mdx mice. Muscle Nerve 33, 66, 2006.
57. Hoffman, E.P., and Escolar, D. Translating mighty mice into neuromuscular therapeutics: is bigger muscle better? Am J Pathol 168, 1775, 2006.
58. Kosnik, P.E., Dennis, R.G., and Vandenburgh, H.H. Tissue engineering skeletal muscle. In: Guilak, F., Butler, D.L., Goldstein, S.A., and Mooney, D.J., eds. Functional Tissue Engineering. New York: Springer, 2003, pp. 377-392.
59. Liao, H., and Zhou, G.-Q. Development and progress of engineering of skeletal muscle tissue. Tissue Eng Part B 15, 2009.
60. Shansky, J., Del Tatto, M., Chromiak, J., and Vandenburgh, H. A simplified method for tissue engineering skeletal muscle organoids in vitro. In Vitro Cell Dev Biol Anim 33, 659, 1997.
61. Bell, E., Ivarsson, B., and Merrill, C. Production of a tissuelike structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci USA 76, 1274, 1979.
62. Powell, C., Smiley, B., Mills, J., and Vandenburgh, H. Mechanical stimulation improves tissue-engineered human skeletal muscle. Am J Physiol Cell Physiol 283, C1557, 2002.
63. Dennis, R.G., Kosnik, P.E., Gilbert, M.E., and Faulkner, J.A. Excitability and contractility of skeletal muscle engineered from primary cultures and cell lines. Am J Physiol Cell Phy-siol 280, C288, 2001.
64. Wakatsuki, T., Fee, J.A., and Elson, E.L. Phenotypic screening for pharmaceuticals using tissue constructs. Curr Pharm Biotechnol 5, 181, 2004.
65. Zimmermann, W.H., Schneiderbanger, K., Schubert, P., Di-die, M., Munzel, F., Heubach, J.F., Kostin, S., Neuhuber, W.L., and Eschenhagen, T. Tissue engineering of a differentiated cardiac muscle construct. Circ Res 90, 223, 2002.
66. Feinberg, A.W., Feigel, A., Shevkoplyas, S.S., Sheehy, S., Whitesides, G.M., and Parker, K.K. Muscular thin films for building actuators and powering devices. Science 317, 1366, 2007.
67. Das, M., Gregory, C.A., Molnar, P., Riedel, L.M., Wilson, K., and Hickman, J.J. A defined system to allow skeletal muscle differentiation and subsequent integration with silicon mi-crostructures. Biomaterials 27, 4374, 2006.
68. Discher, D.E., Janmey, P., and Wang, Y.L. Tissue cells feel and respond to the stiffness of their substrate. Science 310, 1139, 2005.
69. Chaudhuri, O., Parekh, S.H., Lam, W.A., and Fletcher, D.A. Combined atomic force microscopy and side-view optical imaging for mechanical studies of cells. Nat Meth 6, 383, 2009.
70. Vandenburgh, H., Shansky, J., Benesch-Lee, F., Barbata, V., Reid, J., Thorrez, L., Valentini, R., and Crawford, G. A drug screening platform based on the contractility of tissue engineered muscle. Muscle Nerve 37, 438, 2008.
71. Shansky, J., Benesch-Lee, F., Zhang, P., Choi, B.-R., Nath, N., Mende, U., and Vandenburgh, H. Screening drug activity with tissue engineered cardiac muscle. Abstract presented at the Keystone Symposia on Pathological and Physiological Cardiac Hypertrophy, Copper Mountain, CO, 2008.
72. O'Sullivan, S., Nagle, R., McEwen, J.A., and Casey, V. Elastomer rubbers as deflection elements in pressure sensors: investigation of properties using a custom designed programmable elastomer test rig. J Phys D Appl Phys 36, 1910, 2003.
73. Crandall, S.H., Dahl, N.C., and Lardner, T.J. An Introduction to the Mechanics of Solids. New York, NY: McGraw Hill, 1999.
74. Legant, W.R., Pathak, A., Yang, M.T., Deshpande, V.S., McMeeking, R.M., and Chen, C.S. Microfabricated tissue gauges to measure and manipulate forces from 3D micro-tissues. Proc Natl Acad Sci USA 106, 10097, 2009.
75. Vandenburgh, H., Shansky, J., Benesch-Lee, F., Skelly, K., Spinazzola, J., Saponjian, Y., and Tseng, B.S. Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts. FASEB J 2009.
76. Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E.R., Sweeney, H.L., and Rosenthal, N. Localized IGF-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27, 195, 2001.
77. Tobert, J.A. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2, 517, 2003.
78. Thompson, P.D., Clarkson, P.M., and Rosenson, R.S. An assessment of statin safety by muscle experts. Am J Cardiol 97, 69C, 2006.
79. Matsumura, K., and Campbell, K.P. Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve 17, 2, 1994.
80. Morgan, J.E., Beauchamp, J.R., Pagel, C.N., Peckham, M., Ataliotis, P., Jat, P.S., Noble, M.D., Farmer, K., and Partridge, T.A. Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 162, 486, 1994.
81. Grounds, M.D. Two-tiered hypotheses for Duchenne muscular dystrophy. Cell Mol Life Sci 65, 1621, 2008.
82. Yang, S.T., Zhang, X., and Wen, Y. Microbioreactors for high-throughput cytotoxicity assays. Curr Opin Drug Dis-cov Dev 11, 111, 2008.
83. Choi, N.W., Cabodi, M., Held, B., Gleghorn, J.P., Bonassar, L.J., and Stroock, A.D. Microfluidic scaffolds for tissue engineering. Nat Mater 6, 908, 2007.
84. Raimondi, M.T. Engineered tissue as a model to study cell and tissue function from a biophysical perspective. Curr Drug Discov Technol 3, 245, 2006.
85. Roses, A.D. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 7, 807, 2008.
86. Gaud, A., Simon, J.M., Witzel, T., Carre-Pierrat, M., Wermuth, C.G., and Segalat, L. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul Disord 14, 365, 2004.
87. Catoire, H., Pasco, M.Y., bu-Baker, A., Holbert, S., Tourette, C., Brais, B., Rouleau, G.A., Parker, J.A., and Neri, C. Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum Mol Genet 17, 2108, 2008.
88. Steffen, L.S., Guyon, J.R., Vogel, E.D., Beltre, R., Pusack, T.J., Zhou, Y., Zon, L.I., and Kunkel, L.M. Zebrafish orthologs of human muscular dystrophy genes. BMC Genomics 8, 79, 2007.
89. Hirata, H. Zebrafish muscular disease models towards drug discovery. Expert Opin Drug Discov 4, 507, 2009.
90. Parng, C., Seng, W.L., Semino, C., and McGrath, P. Zebra-fish: a preclinical model for drug screening. Assay Drug Dev Technol 1, 41, 2002.
91. Webb, S. iPS cell technology gains momentum in drug discovery. Nat Rev Drug Discov 8, 263, 2009.
92. Pouton, C.W., and Haynes, J.M. Embryonic stem cells as a source of models for drug discovery. Nat Rev Drug Discov 6, 605, 2007.
93. Thomson, H. Bioprocessing of embryonic stem cells for drug discovery. Trends Biotechnol 25, 224, 2007.